Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study
- PMID: 6105763
- DOI: 10.1111/j.1600-0447.1980.tb07084.x
Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study
Abstract
Two depot neuroleptics (flupenthixol plamitate and clopenthixol decanoate) used for at least 15 months were withdrawn in 32 schizophrenic outpatients belonging to the most symptom-free and social cohort of a total patient population. They all had only slight schizophrenic symptoms, were well adapted in the community, and had been free from relapse for at least 2 years before the study. They were assessed by means of rating scales every month during the first six months and then after 9 and 12 months. After the one-year trial 26 patients had relapsed. Moreover, after the control period further 4 out of 6 patients relapsed during the following drug-free year. These results indicate the necessity of a long follow-up period after withdrawal of depot neuroleptics. Moreover, the results suggest that periodical drug-free periods of about 3 months are appropriate in symptom-poor patients during long-term treatment with long-acting antipsychotic drugs.
Similar articles
-
Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate.Acta Psychiatr Scand Suppl. 1980;279:10-28. doi: 10.1111/j.1600-0447.1980.tb07080.x. Acta Psychiatr Scand Suppl. 1980. PMID: 6931470
-
A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.Acta Psychiatr Scand. 1981 Jul;64(1):65-84. doi: 10.1111/j.1600-0447.1981.tb00761.x. Acta Psychiatr Scand. 1981. PMID: 7032224 Clinical Trial.
-
Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome.Acta Psychiatr Scand Suppl. 1980;279:55-63. doi: 10.1111/j.1600-0447.1980.tb07083.x. Acta Psychiatr Scand Suppl. 1980. PMID: 6931473
-
Depot neuroleptics in relapse prevention: advantages and disadvantages.Int Clin Psychopharmacol. 1995 Jan;9 Suppl 5:17-20. doi: 10.1097/00004850-199501005-00004. Int Clin Psychopharmacol. 1995. PMID: 7622829 Review.
-
Antipsychotic medication: clinical guidelines for maintenance therapy.J Clin Psychiatry. 1985 May;46(5 Pt 2):6-15. J Clin Psychiatry. 1985. PMID: 2859281 Review.
Cited by
-
Fluphenazine (oral) versus placebo for schizophrenia.Cochrane Database Syst Rev. 2013 Jul 17;7(7):CD006352. doi: 10.1002/14651858.CD006352.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2018 Jun 12;6:CD006352. doi: 10.1002/14651858.CD006352.pub3. PMID: 23861067 Free PMC article. Updated.
-
Depot fluspirilene for schizophrenia.Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001718. doi: 10.1002/14651858.CD001718.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253464 Free PMC article.
-
Fluphenazine decanoate (depot) and enanthate for schizophrenia.Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Cochrane Database Syst Rev. 2015. PMID: 25654768 Free PMC article.
-
A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966-1993.Sci Eng Ethics. 1997 Oct;3(4):395-406. doi: 10.1007/s11948-997-0043-1. Sci Eng Ethics. 1997. PMID: 11658032 No abstract available.
-
Depot pipotiazine palmitate and undecylenate for schizophrenia.Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD001720. doi: 10.1002/14651858.CD001720.pub2. Cochrane Database Syst Rev. 2004. PMID: 15495016 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical